You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥指首針疫苗注射後十天可產抗體 疫苗保護期至少半年
阿思達克 01-15 12:31
國藥集團中國生物董事長楊曉明表示,從國藥集團中國生物新冠病毒滅活疫苗Ⅲ期臨床試驗的階段性分析看,第一針注射10天後就可以產生抗體,但是,不同人之間抗體產生的差距很大,所以要打第二針。兩針注射後,再過14天,就能產生高滴度抗體,形成有效保護,且全人群中和抗體陽轉率達99%。

他指,正在密切觀察疫苗保護期,目前最早接種疫苗的人已經做了8個多月的觀察,結果顯示依然有效。I期、II期臨床受試者也在繼續觀察,從已經獲得的數據看,半年沒問題,能否保護8個月,正在測定,結果還沒有出來。

他又指,國藥集團中國生物分別在北京和武漢建成了新冠病毒滅活疫苗高等級生物安全生產車間,現已投入規模化生產,並正在進行整個新車間的模擬驗證,通過後,2021年產能可達到10億劑以上。三期產能,擴建將更大。

自去年7月22日正式啟動新冠病毒疫苗的緊急使用以來,接種量不斷增加,目前全國接種劑次已經超過1000萬劑次。(ic/k) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account